Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review

References

• Aicardi J, Levy Gomes A. Clinical and electroencephalographic symptomatology of the ‘genuine’ lennox-gastaut syndrome and its differentiation from other forms of epilepsy of early childhood. Epilepsy Res Suppl. 1992;6:185–193.1418482
   PubMedGoogle Scholar
• Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010;51:676–685. doi:10.1111/j.1528-1167.2010.02522.x20196795
   PubMed Web of Science ®Google Scholar
• Asadi-Pooya AA. Lennox-gastaut syndrome: a comprehensive review. Neurol Sci. 2018;39:403. doi:10.1007/s10072-017-3188-y29124439
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, Ferreira J, Satlin A, et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with lennox-gastaut syndrome: final results from randomized study 303. Eur J Paediatr Neurol. 2019;23(1):126–135. doi:10.1016/j.ejpn.2018.09.01030309816
   PubMed Web of Science ®Google Scholar
• Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res. 1995;12(12):1878–1882. doi:10.1023/A:10162754027238786960
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with lennox-gastaut syndrome. Neurology. 2008;70(21):1950–1958. doi:10.1212/01.wnl.0000303813.95800.0d18401024
   PubMed Web of Science ®Google Scholar
• White HS, Franklin MR, Kupferberg HJ, Schmutz M, Stables JP, Wolf HH. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008;49(7):1213–1220. doi:10.1111/j.1528-1167.2008.01552.x18325020
   PubMed Web of Science ®Google Scholar
• Gilchrist J, Dutton S, Diaz-Bustamante M. Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents. ACS Chem Biol. 2014;9:1204–1212. doi:10.1021/cb500108p24635129
   PubMed Web of Science ®Google Scholar
• Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–1141. doi:10.1111/epi.2008.49.issue-718503564
   PubMed Web of Science ®Google Scholar
• Stephen JL, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs. 2011;25(2):89–107. doi:10.2165/11584860-000000000-0000021254787
   PubMed Web of Science ®Google Scholar
• Inovelon^® Summary of Product Characteristics. 2019.
   Google Scholar
• Yıldız EP, Hızlı Z, Bektaş G, et al. Efficacy of rufinamide in childhood refractory epilepsy. Turk J Pediatr. 2018;60(3):238–243. doi:10.24953/turkjped.2018.03.00230511535
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee CG, Yu HJ, Nam SH, Lee J, Lee M. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res. 2012;2(2):33–37. doi:10.14581/jer.1200924649460
   PubMedGoogle Scholar
• Olson HE, Loddenkemper T, Vendrame M, et al. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011;20(2):344–348. doi:10.1016/j.yebeh.2010.11.02321233024
   PubMed Web of Science ®Google Scholar
• Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in lennox-gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122(3):202–208. doi:10.1111/j.1600-0404.2010.01334.x20199521
   PubMed Web of Science ®Google Scholar
• Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009;14(3):491–495. doi:10.1016/j.yebeh.2008.12.01319162229
   PubMed Web of Science ®Google Scholar
• Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center’s experience. Pediatr Neurol. 2010;43(3):155–158. doi:10.1016/j.pediatrneurol.2010.04.00320691934
   PubMed Web of Science ®Google Scholar
• Cusmai R, Verrotti A, Moavero R, et al. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. Epilepsy Res. 2014;108(3):542–546. doi:10.1016/j.eplepsyres.2014.01.01324548548
   PubMed Web of Science ®Google Scholar
• Coppola G, Grosso S, Franzoni E, et al. Rufinamide in children and adults with lennox-gastautsyndrome: first Italianmulticenterexperience. Seizure. 2010;19(9):587–591. doi:10.1016/j.seizure.2010.09.00820888268
   PubMed Web of Science ®Google Scholar
• Gabriela O, Bozarth XL. Rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy: a retrospective single center study. Epilepsy Res. 2019;106211. doi:10.1016/j.eplepsyres.2019.10621131575436
   PubMed Web of Science ®Google Scholar
• Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–1592. doi:10.1111/epi.1385228782097
   PubMed Web of Science ®Google Scholar
• Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for lennox-gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108(9):1627–1636. doi:10.1016/j.eplepsyres.2014.08.01925219353
   PubMed Web of Science ®Google Scholar
• Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Long-term safety and seizure outcome in Japanese patients with lennox-gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial. Epilepsy Res. 2016;121:1–7. doi:10.1016/j.eplepsyres.2016.01.00226827266
   PubMed Web of Science ®Google Scholar
• Thome-Souza S, Kadish NE, Ramgopal S, et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia. 2014;55(8):1235–1244. doi:10.1111/epi.1268925070475
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, Ferreira JA, Satlin A, et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with lennox-gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. Eur J Paediatr Neurol. 2016;20(3):393–402. doi:10.1016/j.ejpn.2015.12.01526805435
   PubMed Web of Science ®Google Scholar
• Kim SH, Kang HC, Lee JS, Kim HD. Rufinamide efficacy and safety in children aged 1–4 years with lennox-gastaut syndrome. Brain Dev. 2018;40(10):897–903. doi:10.1016/j.braindev.2018.07.02030166208
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee JH, Ryu HW, et al. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalized epilepsy. Epileptic Disord. 2013;15(1):49–54. doi:10.1684/epd.2013.055723531645
   PubMed Web of Science ®Google Scholar
• Kim SH, Eun SH, Kang HC, et al. Rufinamide as an adjuvant treatment in children with lennox-gastautsyndrome. Seizure. 2012;21(4):288–291. doi:10.1016/j.seizure.2012.02.00622421185
   PubMed Web of Science ®Google Scholar
• Lee EH, Yum MS, Ko TS. Effectiveness and tolerability of rufinamide in children and young adults with lennox-gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg. 2013;115(7):926–929. doi:10.1016/j.clineuro.2012.09.02123083943
   PubMed Web of Science ®Google Scholar
• Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav. 2010;17(4):546–548. doi:10.1016/j.yebeh.2010.01.00520185372
   PubMed Web of Science ®Google Scholar
• Nikanorova M, Brandt C, Auvin S, McMurray R. Real-world data on rufinamidetreatment in patients with lennox-gastaut syndrome: results from a Europeannoninterventional registry study. Epilepsy Behav. 2017;76:63–70. doi:10.1016/j.yebeh.2017.08.02628927712
   PubMed Web of Science ®Google Scholar
• Striano P, McMurray R, Santamarina E, Falip M. Rufinamide for the treatment of lennox-gastaut syndrome: evidence from clinical trials and clinical practice. Epileptic Disord. 2018;20(1):13–29. doi:10.1684/epd.2017.095029313492
   PubMed Web of Science ®Google Scholar
• Mueller A, Boor R, Coppola G, et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with dravet syndrome. Epilepsy Behav. 2011;21(3):282–284. doi:10.1016/j.yebeh.2011.04.05721620771
   PubMed Web of Science ®Google Scholar
• Auvin S, Williams B, McMurray R, Kumar D, Perdomo C, Malhotra M. Novel seizure outcomes in patients with lennox‐gastaut syndrome: post hoc analysis of seizure‐free days in rufinamide study 303. Epilepsia Open. 2019;4:275–280. doi:10.1002/epi4.1231431168494
   PubMedGoogle Scholar
• Panebianco M 1, Prabhakar H, Marson AG. Rufinamide add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2018;4:CD011772. doi:10.1002/14651858.CD011772.pub229691835
   PubMed Web of Science ®Google Scholar
• Shahbaz S, Sivamani RK, Konia T, Burrall B. A case of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) related to rufinamide. Dermatol Online J. 2013;19(4):4.
   PubMedGoogle Scholar
• Chambel M, Mascarenhas MI, Regala J, Gouveia C, Prates S. Clinical Stevens-Johnson syndrome and rufinamide: a clinical case. Allergol Immunopathol (Madr). 2013;41(1):68–69. doi:10.1016/j.aller.2011.12.00422306278
   PubMed Web of Science ®Google Scholar
• Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767–778. doi:10.1517/14740338.2012.70582822794330
   PubMed Web of Science ®Google Scholar
• Schimpf R, Veltmann C, Papavassiliu T, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012;9(5):776–781. doi:10.1016/j.hrthm.2012.01.00622245794
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhao H, Chen Z. The efficacy and safety of rufinamide in drug-resistant epilepsy: a meta-analysis of double-blind, randomized, placebo controlled trials. Epilepsy Res. 2016;120:104–110. doi:10.1016/j.eplepsyres.2016.01.00126811934
   PubMed Web of Science ®Google Scholar
• Epidiolex. Summary of Product Characteristics. 2019.
   Google Scholar
• Lagae L, Schoonjans AS, Gammaitoni AR, Galer BS, Ceulemans B. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in lennox-gastaut syndrome. Epilepsia. 2018;59(10):1881–1888. doi:10.1111/epi.1454030146701
   PubMed Web of Science ®Google Scholar
• A study to investigate the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution in children and adults with epileptic encephalopathy including dravet syndrome and lennox-gastaut syndrome. ClinicalTrials.gov Identifier: NCT03936777.
   Google Scholar
• McMurray R, Striano P. Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurol Ther. 2016;5(1):35–43. doi:10.1007/s40120-016-0041-926861566
   PubMedGoogle Scholar
• Grosso S, Coppola G, Dontin SD, et al. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies. Eur J Paediatr Neurol. 2014;18(5):641–645. doi:10.1016/j.ejpn.2014.05.00124912730
   PubMed Web of Science ®Google Scholar